Novogen Limited (NASDAQ:KZIA) Short Interest Down 33.9% in March

Novogen Limited (NASDAQ:KZIA) saw a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 45,079 shares, a decline of 33.9% from the February 26th total of 68,201 shares. Based on an average trading volume of 144,252 shares, the short-interest ratio is currently 0.3 days. Currently, 2.8% of the shares of the stock are sold short.

Analyst Ratings Changes

KZIA has been the subject of a number of research reports. Wall Street Zen lowered shares of Novogen from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Novogen in a research note on Wednesday, January 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $19.00.

Novogen Stock Performance

Novogen stock traded down $0.10 during trading hours on Friday, reaching $7.16. 177,897 shares of the company’s stock traded hands, compared to its average volume of 123,474. Novogen has a fifty-two week low of $2.86 and a fifty-two week high of $17.40. The firm’s 50 day moving average is $7.02 and its 200-day moving average is $7.75.

Novogen (NASDAQ:KZIA) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($1.34) EPS for the quarter.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.